Rohit J Timal1, Judith Kooiman2,3, Yvo W J Sijpkens4, Jean-Paul P M de Vries5,6, Iris J A M Verberk-Jonkers7, Harald F H Brulez8, Marjolijn van Buren9, Aart J van der Molen10, Suzanne C Cannegieter2,11, Hein Putter12, Wilbert B van den Hout12, J Wouter Jukema1, Ton J Rabelink13, Menno V Huisman2. 1. Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands. 2. Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands. 3. Department of Obstetrics and Gynaecology, Utrecht University Medical Center, Utrecht, the Netherlands. 4. Department of Internal Medicine, Haaglanden Medisch Centrum Bronovo, The Hague, the Netherlands. 5. Department of Vascular Surgery, St Antonius Hospital, Nieuwegein, the Netherlands. 6. Department of Vascular Surgery, University Medical Centre Groningen, Groningen, the Netherlands. 7. Department of Internal Medicine, Maasstad Hospital, Rotterdam, the Netherlands. 8. Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands. 9. Department of Internal Medicine, Haga Teaching Hospital, The Hague, the Netherlands. 10. Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands. 11. Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands. 12. Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands. 13. Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Abstract
Importance: Prevention of postcontrast acute kidney injury in patients with stage 3 chronic kidney disease (CKD) by means of prehydration has been standard care for years. However, evidence for the need for prehydration in this group is limited. Objective: To assess the renal safety of omitting prophylactic prehydration prior to iodine-based contrast media administration in patients with stage 3 CKD. Design, Setting, and Participants: The Kompas trial was a multicenter, noninferiority, randomized clinical trial conducted at 6 hospitals in the Netherlands in which 523 patients with stage 3 CKD were randomized in a 1:1 ratio to receive no prehydration or prehydration with 250 mL of 1.4% sodium bicarbonate administered in a 1-hour infusion before undergoing elective contrast-enhanced computed tomography from April 2013 through September 2016. Final follow-up was completed in September 2017. Data were analyzed from January 2018 to June 2019. Interventions: In total, 262 patients were allocated to the no prehydration group and 261 were allocated to receive prehydration. Analysis on the primary end point was available in 505 patients (96.6%). Main Outcomes and Measures: The primary end point was the mean relative increase in serum creatinine level 2 to 5 days after contrast administration compared with baseline (noninferiority margin of less than 10% increase in serum creatinine level). Secondary outcomes included the incidence of postcontrast acute kidney injury 2 to 5 days after contrast administration, mean relative increase in creatinine level 7 to 14 days after contrast administration, incidences of acute heart failure and renal failure requiring dialysis, and health care costs. Results: Of 554 patients randomized, 523 were included in the intention-to-treat analysis. The median (interquartile range) age was 74 (67-79) years; 336 (64.2%) were men and 187 (35.8%) were women. The mean (SD) relative increase in creatinine level 2 to 5 days after contrast administration compared with baseline was 3.0% (10.5) in the no prehydration group vs 3.5% (10.3) in the prehydration group (mean difference, 0.5; 95% CI, -1.3 to 2.3; P < .001 for noninferiority). Postcontrast acute kidney injury occurred in 11 patients (2.1%), including 7 of 262 (2.7%) in the no prehydration group and 4 of 261 (1.5%) in the prehydration group, which resulted in a relative risk of 1.7 (95% CI, 0.5-5.9; P = .36). None of the patients required dialysis or developed acute heart failure. Subgroup analyses showed no evidence of statistical interactions between treatment arms and predefined subgroups. Mean hydration costs were €119 (US $143.94) per patient in the prehydration group compared with €0 (US $0) in the no prehydration group (P < .001). Other health care costs were similar. Conclusions and Relevance: Among patients with stage 3 CKD undergoing contrast-enhanced computed tomography, withholding prehydration did not compromise patient safety. The findings of this study support the option of not giving prehydration as a safe and cost-efficient measure. Trial Registration: Netherlands Trial Register Identifier: NTR3764.
RCT Entities:
Importance: Prevention of postcontrast acute kidney injury in patients with stage 3 chronic kidney disease (CKD) by means of prehydration has been standard care for years. However, evidence for the need for prehydration in this group is limited. Objective: To assess the renal safety of omitting prophylactic prehydration prior to iodine-based contrast media administration in patients with stage 3 CKD. Design, Setting, and Participants: The Kompas trial was a multicenter, noninferiority, randomized clinical trial conducted at 6 hospitals in the Netherlands in which 523 patients with stage 3 CKD were randomized in a 1:1 ratio to receive no prehydration or prehydration with 250 mL of 1.4% sodium bicarbonate administered in a 1-hour infusion before undergoing elective contrast-enhanced computed tomography from April 2013 through September 2016. Final follow-up was completed in September 2017. Data were analyzed from January 2018 to June 2019. Interventions: In total, 262 patients were allocated to the no prehydration group and 261 were allocated to receive prehydration. Analysis on the primary end point was available in 505 patients (96.6%). Main Outcomes and Measures: The primary end point was the mean relative increase in serum creatinine level 2 to 5 days after contrast administration compared with baseline (noninferiority margin of less than 10% increase in serum creatinine level). Secondary outcomes included the incidence of postcontrast acute kidney injury 2 to 5 days after contrast administration, mean relative increase in creatinine level 7 to 14 days after contrast administration, incidences of acute heart failure and renal failure requiring dialysis, and health care costs. Results: Of 554 patients randomized, 523 were included in the intention-to-treat analysis. The median (interquartile range) age was 74 (67-79) years; 336 (64.2%) were men and 187 (35.8%) were women. The mean (SD) relative increase in creatinine level 2 to 5 days after contrast administration compared with baseline was 3.0% (10.5) in the no prehydration group vs 3.5% (10.3) in the prehydration group (mean difference, 0.5; 95% CI, -1.3 to 2.3; P < .001 for noninferiority). Postcontrast acute kidney injury occurred in 11 patients (2.1%), including 7 of 262 (2.7%) in the no prehydration group and 4 of 261 (1.5%) in the prehydration group, which resulted in a relative risk of 1.7 (95% CI, 0.5-5.9; P = .36). None of the patients required dialysis or developed acute heart failure. Subgroup analyses showed no evidence of statistical interactions between treatment arms and predefined subgroups. Mean hydration costs were €119 (US $143.94) per patient in the prehydration group compared with €0 (US $0) in the no prehydration group (P < .001). Other health care costs were similar. Conclusions and Relevance: Among patients with stage 3 CKD undergoing contrast-enhanced computed tomography, withholding prehydration did not compromise patient safety. The findings of this study support the option of not giving prehydration as a safe and cost-efficient measure. Trial Registration: Netherlands Trial Register Identifier: NTR3764.
Authors: J Kooiman; Y W J Sijpkens; M van Buren; J H M Groeneveld; S R S Ramai; A J van der Molen; N J M Aarts; C J van Rooden; S C Cannegieter; H Putter; T J Rabelink; M V Huisman Journal: J Thromb Haemost Date: 2014-09-26 Impact factor: 5.824
Authors: Louis C Coyle; Antonio Rodriguez; Robert E Jeschke; Anabela Simon-Lee; Kevin C Abbott; Allen J Taylor Journal: Am Heart J Date: 2006-05 Impact factor: 4.749
Authors: Fulvio Stacul; Aart J van der Molen; Peter Reimer; Judith A W Webb; Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Peter Aspelin; Marie-France Bellin; Olivier Clement; Gertraud Heinz-Peer Journal: Eur Radiol Date: 2011-08-25 Impact factor: 5.315
Authors: Judith Kooiman; Sharif M Pasha; Wendy Zondag; Yvo W J Sijpkens; Aart J van der Molen; Menno V Huisman; Olaf M Dekkers Journal: Eur J Radiol Date: 2011-12-15 Impact factor: 3.528
Authors: Estelle C Nijssen; Roger J Rennenberg; Patty J Nelemans; Brigitte A Essers; Marga M Janssen; Marja A Vermeeren; Vincent van Ommen; Joachim E Wildberger Journal: Lancet Date: 2017-02-21 Impact factor: 79.321
Authors: Judith Kooiman; Yvo W J Sijpkens; Jean-Paul P M de Vries; Harald F H Brulez; Jaap F Hamming; Aart J van der Molen; Nico J M Aarts; Suzanne C Cannegieter; Hein Putter; Renate Swarts; Wilbert B van den Hout; Ton J Rabelink; Menno V Huisman Journal: Nephrol Dial Transplant Date: 2014-02-27 Impact factor: 5.992
Authors: Irene L Noronha; Guilherme P Santa-Catharina; Lucia Andrade; Venceslau A Coelho; Wilson Jacob-Filho; Rosilene M Elias Journal: Front Med (Lausanne) Date: 2022-09-15
Authors: Peter Pickkers; Michael Darmon; Eric Hoste; Michael Joannidis; Matthieu Legrand; Marlies Ostermann; John R Prowle; Antoine Schneider; Miet Schetz Journal: Intensive Care Med Date: 2021-07-02 Impact factor: 17.440